Repository logo
 

Multiple Long-Term Conditions, Co-Long-Term Conditions and Polyvascular Disease: Considerations for Evidence Synthesis and Meta-Analyses

aut.relation.issue3
aut.relation.journalCochrane Evidence Synthesis and Methods
aut.relation.volume3
dc.contributor.authorMead, Gillian
dc.contributor.authorTodhunter‐Brown, Alex
dc.contributor.authorAbaraogu, Ukachukwu
dc.contributor.authorBarugh, Amanda
dc.contributor.authorChauhan, Arohi
dc.contributor.authorLopez, Juan Erviti
dc.contributor.authorFeigin, Valery
dc.contributor.authorKshatri, Jaya Singh
dc.contributor.authorMizuno, Atsushi
dc.contributor.authorPati, Sanghamitra
dc.contributor.authorPrice, Jackie
dc.contributor.authorProvidência, Rui
dc.contributor.authorStansby, Gerry
dc.contributor.authorTaylor, Rod
dc.contributor.authorWilliams, David J
dc.contributor.authorWright, James M
dc.contributor.authorWu, Simiao
dc.contributor.authorFlicker, Leon
dc.date.accessioned2025-04-08T20:40:44Z
dc.date.available2025-04-08T20:40:44Z
dc.date.issued2025
dc.description.abstractCochrane's scientific strategy for 2025 to 2030 has four research priorities, including improving the lives of people living with multiple chronic conditions. The purpose of this article written by the Cochrane Thematic Group in Heart, Stroke and Circulation is to explore considerations around multiple chronic conditions (also referred to as ‘multiple long‐term conditions’ i.e. two or more long‐term conditions) in systematic reviews. Rather than using the term ‘comorbidity’, we introduce a new term ‘co‐long‐term conditions’. We also explore how to define ‘polyvascular disease’. We suggest that review authors consider co‐long‐term conditions and multiple long‐term conditions in their reviews e.g. extract data about how primary studies address co‐long‐term conditions, perform subgroup analyses according to presence or not of co‐long‐term conditions, and include a section in the discussion about how well participants with co‐long‐term conditions were represented in the primary studies. This is especially pertinent for reviews addressing heart, circulatory or stroke disease, and polyvascular disease.
dc.identifier.citationCochrane Evidence Synthesis and Methods, ISSN: 2832-9023 (Print); 2832-9023 (Online), Wiley, 3(3). doi: 10.1002/cesm.70027
dc.identifier.doi10.1002/cesm.70027
dc.identifier.issn2832-9023
dc.identifier.issn2832-9023
dc.identifier.urihttp://hdl.handle.net/10292/19007
dc.languageen
dc.publisherWiley
dc.relation.urihttps://onlinelibrary.wiley.com/doi/10.1002/cesm.70027
dc.rights© 2025 The Author(s). Cochrane Evidence Synthesis and Methods published by John Wiley & Sons Ltd on behalf of The Cochrane Collaboration. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
dc.rights.accessrightsOpenAccess
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleMultiple Long-Term Conditions, Co-Long-Term Conditions and Polyvascular Disease: Considerations for Evidence Synthesis and Meta-Analyses
dc.typeJournal Article
pubs.elements-id598516

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Cochrane Evidence Synthesis and Methods - 2025 - Mead - Multiple Long‐Term Conditions Co‐Long‐Term Conditions and (1).pdf
Size:
311.66 KB
Format:
Adobe Portable Document Format
Description:
Journal article